OTC Asthma Inhaler Labeling "Strengthening" Called For By AMA
This article was originally published in The Tan Sheet
Executive Summary
The AMA House of Delegates adopted a resolution calling for "strengthening the product labeling for over-the-counter (OTC) epinephrine inhalers to better educate users about patterns of inappropriate use" at its annual meeting in Chicago June 20-24.
You may also be interested in...
Primatene Mist Availability Not “Essential,” Advisory Panel Says
Questions about the appropriateness of asthma for OTC treatment led to an FDA advisory panel vote in favor of removing Wyeth's Primatene Mistfrom the market during a Jan. 24 meeting in Bethesda, Md
Primatene Mist Availability Not “Essential,” Advisory Panel Says
Questions about the appropriateness of asthma for OTC treatment led to an FDA advisory panel vote in favor of removing Wyeth's Primatene Mistfrom the market during a Jan. 24 meeting in Bethesda, Md
Primatene Mist Availability Not “Essential,” Advisory Panel Says
Questions about the appropriateness of asthma for OTC treatment led to an FDA advisory panel vote in favor of removing Wyeth's Primatene Mistfrom the market during a Jan. 24 meeting in Bethesda, Md